Hemp State Legislation: Comprehensive Guide to U.S. Hemp Laws by State

Executive Summary

State legislatures across the United States are actively reshaping hemp regulation in 2026, with at least 34 states considering bills that address intoxicating hemp-derived cannabinoids, product testing standards, and retail licensing frameworks. The flurry of legislative activity follows years of regulatory ambiguity created by the 2018 Farm Bill, which federally legalized hemp containing no more than 0.3% delta-9 THC by dry weight but left states to grapple with novel cannabinoids like delta-8 THC, THCA, and HHC. As of May 2026, twelve states have enacted comprehensive hemp regulations this legislative session, while another fifteen have bills advancing through committee. The economic stakes are substantial: the hemp-derived cannabinoid market generated an estimated $2.8 billion in retail sales in 2025, according to the Hemp Industry Daily, with projections reaching $4.1 billion by 2027. State actions range from outright bans on intoxicating hemp products to carefully structured regulatory frameworks that establish testing requirements, potency limits, age restrictions, and licensing systems. The patchwork of state approaches creates operational complexity for multi-state operators while generating significant uncertainty for retailers, farmers, and consumers navigating rapidly shifting legal landscapes.

Why This Matters

Hemp state legislation directly impacts a $2.8 billion industry, approximately 94,000 jobs across cultivation and retail, and millions of consumers who rely on hemp-derived products for wellness, recreation, and medical purposes. The regulatory decisions states make in 2026 will determine market access for thousands of small businesses. According to the National Hemp Association, the United States had approximately 16,400 licensed hemp farmers in 2025, cultivating 54,300 acres. These farmers depend on clear regulatory frameworks to make planting decisions, secure financing, and access markets. Ambiguous or restrictive state legislation can render entire harvests unmarketable overnight. For retailers, the stakes are equally high. An estimated 23,000 retail locations nationwide sell hemp-derived cannabinoid products, from dedicated CBD shops to convenience stores and gas stations. Many of these businesses operate on thin margins and cannot afford compliance costs associated with rapidly changing state requirements or the risk of inventory confiscation under new restrictions. Consumers face direct health and safety implications. Without standardized testing requirements and potency limits, products on shelves may contain inaccurate labeling, harmful contaminants, or dangerously high cannabinoid concentrations. The FDA has issued multiple warning letters regarding hemp products with undisclosed THC levels, heavy metal contamination, and microbial hazards. Multi-state operators (MSOs) in the regulated cannabis industry watch hemp legislation closely because intoxicating hemp products compete directly with state-licensed cannabis programs. In states where hemp-derived delta-8 THC or THCA flower remains legal and untaxed, licensed dispensaries report revenue impacts of 15-30%, according to industry surveys. This dynamic creates pressure on state legislators to either regulate hemp more strictly or reduce cannabis taxes to level the competitive playing field.

Background and History

The modern hemp regulatory landscape emerged from the 2018 Farm Bill, but the plant's legal status has oscillated dramatically over the past century, from ubiquitous agricultural commodity to controlled substance and back again.

Pre-Prohibition Era (Before 1937)

Hemp cultivation was widespread in colonial America and the early United States. Farmers grew hemp for fiber used in rope, textiles, and paper. George Washington and Thomas Jefferson both cultivated hemp on their estates. The plant was an ordinary agricultural commodity with no special legal restrictions. Industrial hemp and psychoactive cannabis were not legally distinguished.

The Marihuana Tax Act of 1937

The Marihuana Tax Act of 1937 effectively criminalized cannabis cultivation, including hemp, by imposing prohibitive taxes and registration requirements. While the Act theoretically allowed continued hemp cultivation for industrial purposes, the administrative burden made it economically unviable. Hemp acreage in the United States dropped precipitously.

World War II Hemp for Victory

During World War II, the U.S. Department of Agriculture launched the "Hemp for Victory" campaign, encouraging farmers to grow hemp for military supplies after Japanese control of Philippine manila hemp supplies created shortages. The government issued permits for approximately 150,000 acres of hemp cultivation between 1942 and 1945. After the war ended, hemp cultivation again became impractical under federal restrictions.

The Controlled Substances Act of 1970

The Controlled Substances Act (CSA), codified at 21 U.S.C. § 812, classified marijuana as a Schedule I controlled substance. The CSA made no distinction between psychoactive cannabis and industrial hemp. All Cannabis sativa cultivation became federally illegal, with narrow exceptions for DEA-approved research. For nearly five decades, American hemp cultivation essentially ceased.

State Hemp Pilot Programs (2014-2018)

The 2014 Farm Bill (Agricultural Act of 2014, Section 7606) created a limited exception allowing state departments of agriculture and higher education institutions to establish hemp pilot programs for research purposes. The provision defined hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis. By 2018, 41 states had established pilot programs, cultivating approximately 78,000 acres collectively. These programs demonstrated hemp's agricultural viability and generated demand for broader legalization.

The 2018 Farm Bill

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from the CSA's definition of marijuana. Section 10113 defined hemp as cannabis with no more than 0.3% delta-9 THC by dry weight and explicitly legalized its cultivation, processing, and sale. The legislation transferred regulatory authority from the DEA to the U.S. Department of Agriculture (USDA), which was tasked with approving state and tribal hemp production plans. The 2018 Farm Bill preserved state authority to regulate hemp more restrictively than federal law. Section 10114 explicitly stated that nothing in the law preempts state or tribal laws that regulate hemp production more stringently or prohibit it entirely. This provision created the legal foundation for the current patchwork of state approaches.

The USDA Interim Final Rule (2019-2021)

On October 31, 2019, the USDA published its Interim Final Rule establishing the U.S. Domestic Hemp Production Program. The rule set testing protocols requiring hemp to be tested within 15 days of harvest using DEA-registered laboratories. It established a 0.3% total THC limit (including THCA converted to delta-9 THC equivalent) and required disposal of non-compliant crops. The rule's stringent testing timeline and total THC measurement created significant compliance challenges for farmers.

The USDA Final Rule (2021)

The USDA published its Final Rule on January 19, 2021, making several adjustments based on public comment. The rule maintained the 0.3% total THC limit but provided greater flexibility in sampling procedures and remediation options for non-compliant crops. It established a framework for USDA approval of state and tribal hemp plans, with USDA licenses available in states without approved plans. As of May 2026, 73 state and tribal hemp production plans have received USDA approval.

The Delta-8 THC Market Explosion (2020-2023)

Beginning in 2020, manufacturers discovered they could convert CBD derived from legal hemp into delta-8 THC through chemical synthesis. Delta-8 THC is a psychoactive cannabinoid that occurs naturally in cannabis in trace amounts but can be produced in large quantities from CBD isolate. Manufacturers argued that delta-8 THC derived from legal hemp was itself legal under the 2018 Farm Bill. The delta-8 THC market grew explosively, reaching an estimated $2 billion in sales by 2022. Products appeared in gas stations, convenience stores, and online retailers nationwide. The DEA issued guidance in August 2020 stating that synthetically derived THC remained Schedule I controlled substances, but enforcement was limited and legal interpretation remained contested.

State Regulatory Response (2021-2025)

States responded to intoxicating hemp products with divergent approaches. Between 2021 and 2025, eighteen states enacted outright bans on delta-8 THC and similar hemp-derived intoxicants. Another twelve states established regulatory frameworks with testing requirements, potency limits, and age restrictions. The remaining states took no action, allowing hemp-derived cannabinoid markets to operate largely unregulated. The emergence of THCA flower in 2023-2024 created additional regulatory challenges. THCA (tetrahydrocannabinolic acid) is the non-psychoactive precursor to delta-9 THC found in raw cannabis. When heated through smoking or vaping, THCA converts to psychoactive delta-9 THC. Because the 2018 Farm Bill defines hemp based on delta-9 THC content measured before decarboxylation, raw cannabis flower high in THCA but low in delta-9 THC technically qualifies as legal hemp. Retailers began selling THCA flower that was functionally identical to marijuana flower sold in licensed dispensaries, creating direct competition with state-regulated cannabis programs.

The 2026 Legislative Wave

The 2026 state legislative sessions have seen unprecedented activity on hemp regulation. As of May 14, 2026, legislators in 34 states have introduced bills addressing hemp-derived cannabinoids. The legislative activity reflects growing pressure from multiple stakeholders: licensed cannabis operators seeking competitive parity, public health officials concerned about unregulated intoxicating products, law enforcement seeking clear legal standards, and hemp industry participants seeking regulatory clarity to enable legitimate business operations.

Key Players

U.S. Department of Agriculture

The USDA oversees hemp production through its Agricultural Marketing Service. The agency approves state and tribal hemp plans, issues federal licenses in states without approved plans, and maintains the national hemp database. The USDA has regulatory authority over cultivation and production but limited authority over hemp-derived products once they enter commerce.

Food and Drug Administration

The FDA retains authority over hemp-derived products intended for human or animal consumption under the Federal Food, Drug, and Cosmetic Act. The agency has issued numerous warning letters to companies making unsubstantiated health claims or selling products with safety concerns. However, the FDA has not established a comprehensive regulatory framework for hemp-derived CBD or other cannabinoids, creating a regulatory vacuum that states have attempted to fill.

Drug Enforcement Administration

The DEA maintains that synthetically derived cannabinoids remain Schedule I controlled substances under 21 U.S.C. § 812, regardless of their hemp origin. The agency's August 2020 interim final rule stated that "all synthetically derived tetrahydrocannabinols remain schedule I controlled substances." However, the DEA has conducted limited enforcement against hemp-derived cannabinoid products, and legal challenges to its interpretation remain ongoing.

National Hemp Association

The National Hemp Association represents hemp farmers, processors, and businesses. The organization advocates for federal regulatory clarity and state frameworks that allow legitimate hemp commerce while implementing appropriate safety standards. The association has supported testing requirements, age restrictions, and licensing systems while opposing outright bans.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable is a coalition of hemp companies and stakeholders that advocates for federal policy supporting the hemp industry. The organization has pushed for FDA regulatory action on CBD and supported state legislation that regulates rather than prohibits hemp-derived cannabinoids.

Cannabis Regulators Association

The Cannabis Regulators Association (formerly CANNRA) represents state cannabis regulatory agencies. The organization has advocated for state authority to regulate intoxicating hemp products similarly to marijuana and has raised concerns about unregulated hemp products undermining state-licensed cannabis programs.

Multi-State Operators

Large cannabis MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have lobbied state legislatures to restrict intoxicating hemp products or subject them to the same testing, taxation, and licensing requirements as state-regulated cannabis. These companies argue that unregulated hemp products create unfair competition and public safety risks.

National Association of Convenience Stores

The National Association of Convenience Stores represents retailers that have become major distribution channels for hemp-derived products. The organization has generally opposed outright bans while supporting reasonable regulatory frameworks that allow continued sales with appropriate age verification and product standards.

Public Health Advocacy Groups

Organizations including the American Academy of Pediatrics, the American Medical Association, and Smart Approaches to Marijuana have raised concerns about intoxicating hemp products, particularly regarding youth access, lack of testing standards, and unclear labeling. These groups have generally supported stricter state regulation or prohibition of intoxicating hemp-derived cannabinoids.

Legal and Regulatory Framework

The legal framework governing hemp-derived cannabinoids involves overlapping federal and state authority, with the 2018 Farm Bill establishing federal hemp legality while preserving state power to regulate more restrictively. The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition is critical because it determines what qualifies as legal hemp versus marijuana under federal law. Section 297D(c) of the Farm Bill explicitly preserves state authority: "Nothing in this section preempts or limits any law of a State or Indian Tribe that regulates the production of hemp and is more stringent than this subchapter." This provision means states can ban hemp production entirely, restrict hemp-derived products, or impose additional regulatory requirements beyond federal standards. The Controlled Substances Act at 21 U.S.C. § 802(16) was amended by the 2018 Farm Bill to exclude hemp from the definition of marijuana. However, the CSA's definition of THC as a Schedule I controlled substance remains contested. The DEA interprets synthetically derived THC as remaining illegal regardless of hemp origin, while hemp industry participants argue that cannabinoids derived from legal hemp are themselves legal under the Farm Bill. The Federal Food, Drug, and Cosmetic Act at 21 U.S.C. § 301 et seq. gives the FDA authority over products intended for human or animal consumption. The FDA has taken the position that CBD and other cannabinoids cannot be added to food or sold as dietary supplements without FDA approval. However, the agency has not established a regulatory pathway for hemp-derived cannabinoids, and enforcement has been limited primarily to warning letters for egregious violations. State hemp laws vary dramatically. Some states have adopted the USDA's regulatory framework with minimal additional requirements. Others have established comprehensive state-specific regulations covering cultivation, processing, testing, labeling, and retail sales. At least fourteen states have explicitly banned delta-8 THC and similar intoxicating hemp-derived cannabinoids as of May 2026. The legal status of specific cannabinoids remains contested. Delta-8 THC, delta-10 THC, THC-O, and HHC are all psychoactive cannabinoids that can be synthesized from hemp-derived CBD. Courts have not definitively resolved whether these substances are legal under the 2018 Farm Bill or controlled under the CSA. The Fifth Circuit Court of Appeals is currently considering a case challenging the DEA's authority to regulate hemp-derived delta-8 THC, with oral arguments scheduled for July 2026. THCA presents unique legal questions. Because THCA is non-psychoactive and converts to delta-9 THC only when heated, cannabis flower high in THCA but measuring below 0.3% delta-9 THC technically qualifies as hemp under the statutory definition. However, several states have amended their hemp definitions to include total potential THC (THCA converted to delta-9 equivalent) or have explicitly classified high-THCA flower as marijuana regardless of delta-9 THC measurement.

State-by-State Breakdown

As of May 2026, state approaches to hemp-derived cannabinoids fall into four categories: comprehensive regulation, outright prohibition, limited restrictions, and no specific action.

California

California enacted Assembly Bill 45 in October 2025, establishing a comprehensive regulatory framework for hemp-derived cannabinoids. The law requires all intoxicating hemp products to be sold through state-licensed cannabis retailers, subject to the same testing standards as marijuana products. Hemp-derived products must comply with California's cannabis testing requirements under 16 CCR § 5700 et seq., including analysis for potency, pesticides, heavy metals, and microbial contaminants. The law took effect January 1, 2026, and prohibits sales of intoxicating hemp products outside the licensed cannabis supply chain. California defines intoxicating hemp products as those containing more than 0.3 mg of total THC per serving or 2 mg per package.

New York

New York's Cannabis Control Board issued emergency regulations in March 2026 requiring all hemp-derived cannabinoid products containing more than 0.3% total THC to be sold exclusively through licensed adult-use cannabis dispensaries. The regulations establish a 10 mg THC limit per serving and 100 mg per package for hemp-derived edibles sold through licensed channels. Retailers selling non-compliant products face fines up to $10,000 per violation. The state Office of Cannabis Management has issued approximately 230 violation notices to convenience stores and smoke shops since the regulations took effect.

Florida

Florida has not enacted comprehensive hemp cannabinoid legislation as of May 2026, but Senate Bill 1698 is currently advancing through committee. The bill would establish a state hemp program separate from the medical marijuana program, with testing requirements, potency limits of 5 mg delta-9 THC per serving, and a 21-year minimum age for purchase. The Florida Department of Agriculture and Consumer Services would oversee licensing. The bill has support from hemp industry stakeholders but faces opposition from licensed medical marijuana operators who argue it would create unfair competition.

Texas

Texas enacted House Bill 2593 in May 2025, banning the manufacture and sale of products containing delta-8 THC, delta-9 THC above 0.3%, THCA, or other intoxicating cannabinoids derived from hemp. The law took effect September 1, 2025. The Texas Department of State Health Services has conducted compliance sweeps resulting in seizures of non-compliant products from approximately 1,400 retail locations. Several hemp companies have filed legal challenges arguing the ban exceeds state authority under the 2018 Farm Bill, with cases pending in federal district court.

Ohio

Ohio passed House Bill 210 in December 2025, establishing a regulatory framework for hemp-derived cannabinoids that took effect March 1, 2026. The law requires all hemp products containing intoxicating cannabinoids to be sold through the state's existing medical marijuana dispensaries or through newly licensed hemp retailers. Products must be tested by state-certified laboratories and comply with potency limits of 10 mg THC per serving. The Ohio Department of Commerce has issued 89 hemp retailer licenses as of May 2026. The law prohibits sales to individuals under 21 and bans hemp products designed to appeal to children.

Michigan

Michigan's Cannabis Regulatory Agency issued guidance in February 2026 clarifying that hemp-derived products containing more than 0.5 mg of any intoxicating cannabinoid per serving must be sold through state-licensed marijuana retailers. The guidance does not have the force of law but signals the state's enforcement priorities. The Michigan Legislature is considering Senate Bill 891, which would codify these restrictions and establish civil penalties for violations. Michigan allows adult-use cannabis sales and has approximately 1,200 licensed marijuana retailers statewide.

Colorado

Colorado enacted House Bill 1317 in June 2025, requiring all hemp-derived products containing intoxicating cannabinoids to comply with the state's marijuana regulations under the Colorado Marijuana Code, 44-10-101 C.R.S. et seq. Products must be sold through licensed marijuana stores, tested by state-certified laboratories, and comply with packaging and labeling requirements including child-resistant packaging and THC warning labels. The law established a six-month transition period that ended December 31, 2025. Colorado's Marijuana Enforcement Division has issued approximately 340 violation notices for non-compliant hemp product sales.

Illinois

Illinois has taken a restrictive approach, with the Department of Agriculture issuing guidance in 2024 that delta-8 THC and similar intoxicating hemp-derived cannabinoids are considered cannabis under state law and can only be sold through licensed dispensaries. The Illinois Cannabis Regulation and Tax Act, 410 ILCS 705, defines cannabis broadly to include all parts of the Cannabis sativa plant. The state has not enacted specific hemp cannabinoid legislation, but enforcement actions have effectively prohibited sales outside the licensed cannabis system.

Oregon

Oregon passed House Bill 3000 in July 2025, establishing a regulatory framework for artificially derived cannabinoids. The law requires products containing delta-8 THC, THC-O, or other synthesized cannabinoids to be sold through Oregon Liquor and Cannabis Commission-licensed retailers. Naturally occurring hemp-derived CBD products remain available through general retail channels. The law establishes testing requirements and prohibits products with total THC exceeding 50 mg per package. Oregon's framework took effect January 1, 2026.

North Carolina

North Carolina has not enacted comprehensive hemp cannabinoid regulations as of May 2026. The state's hemp program operates under the North Carolina Industrial Hemp Commission. Senate Bill 711, introduced in March 2026, would establish potency limits, testing requirements, and age restrictions for hemp-derived cannabinoids but would not require sales through a licensed system. The bill remains in committee. North Carolina does not have a legal adult-use or medical marijuana program, making it one of the largest markets for hemp-derived intoxicating products.

Georgia

Georgia enacted Senate Bill 494 in May 2025, banning the sale of products containing delta-8 THC, delta-10 THC, THC-O, or THCA in concentrations that could produce intoxication. The law defines intoxicating hemp products as those containing more than 0.3% total THC by weight. The Georgia Department of Agriculture oversees enforcement. The law took effect July 1, 2025, and includes civil penalties up to $5,000 per violation. Georgia allows low-THC medical cannabis oil for registered patients but does not permit dispensary sales or in-state cultivation.

Washington

Washington's Liquor and Cannabis Board issued emergency rules in January 2026 requiring all hemp products containing more than 0.3% total THC to be sold through state-licensed cannabis retailers. The rules establish testing requirements identical to those for marijuana products under WAC 314-55-102. Washington's approach integrates intoxicating hemp products into the existing cannabis regulatory system. The state has approximately 500 licensed cannabis retailers. Legislation to codify these rules permanently is expected to pass in the 2027 session.

Minnesota

Minnesota enacted a comprehensive hemp-derived cannabinoid law in 2022 that remains in effect in 2026. The law allows hemp-derived edibles containing up to 5 mg THC per serving and 50 mg per package to be sold through general retail channels with age restrictions. Products must be tested by ISO-accredited laboratories and comply with labeling requirements. Minnesota also legalized adult-use cannabis in 2023, creating parallel regulatory systems for hemp-derived and marijuana-derived products. The state Office of Cannabis Management oversees both programs.

Virginia

Virginia passed House Bill 2293 in March 2026, establishing a regulatory framework for hemp-derived cannabinoids that will take effect January 1, 2027. The law requires retailers to obtain a state license, establishes testing requirements, and limits products to 2 mg delta-9 THC per serving and 25 mg per package. The Virginia Department of Agriculture and Consumer Services will administer the program. Virginia legalized simple possession of marijuana in 2021 but has not yet established retail sales, making hemp-derived products the primary legal source of intoxicating cannabinoids for adult consumers.

Arizona

Arizona's Department of Health Services issued guidance in 2024 stating that hemp-derived products containing intoxicating levels of THC must comply with the state's marijuana regulations under the Arizona Medical Marijuana Act and the Smart and Safe Arizona Act. The guidance has not been codified in statute, but the state has conducted enforcement actions against retailers selling non-compliant hemp products. Arizona voters approved adult-use cannabis in 2020, and the state has approximately 170 licensed dispensaries.

Market and Business Implications

State hemp legislation directly impacts market access, capital flows, and competitive dynamics across the $2.8 billion hemp-derived cannabinoid sector and the $30 billion state-licensed cannabis industry. For hemp operators, restrictive state legislation can eliminate market access overnight. A hemp processor in Texas that manufactured delta-8 THC products saw its in-state distribution channels disappear when House Bill 2593 took effect in September 2025. The company pivoted to out-of-state sales but reported a 60% revenue decline in the fourth quarter of 2025. Similar disruptions have occurred in Georgia, Colorado, and other states that banned or heavily restricted hemp-derived intoxicating products. Conversely, states that establish clear regulatory frameworks create opportunities for compliant operators. In Minnesota, licensed hemp edible manufacturers reported 40% revenue growth in 2025 following implementation of the state's hemp-derived cannabinoid law. Clear rules enabled retailers to stock products confidently and allowed manufacturers to secure financing and make long-term investments. The testing requirement trend creates new market opportunities for analytical laboratories. States requiring hemp products to undergo potency, pesticide, heavy metal, and microbial testing have driven demand for accredited laboratory services. Laboratory capacity constraints have emerged in several states, with turnaround times for hemp product testing extending to 3-4 weeks in California and New York during peak periods in early 2026. Multi-state operators in the licensed cannabis industry view hemp legislation as critical to protecting their market position. In states where intoxicating hemp products remain widely available through convenience stores and smoke shops, licensed dispensaries report significant competitive pressure. A survey of Michigan dispensaries conducted in March 2026 found that 68% reported revenue impacts from hemp-derived product competition, with estimated losses averaging 18% of potential sales. The taxation differential between hemp-derived and marijuana-derived products creates substantial competitive advantages for hemp. Hemp products generally face only standard sales tax, while marijuana products in most states face excise taxes ranging from 10% to 37%. In California, where marijuana faces a 15% excise tax plus local taxes that can reach 10%, hemp-derived products sold outside the licensed system have a 25-30% price advantage before the state's 2026 regulatory changes took effect. Capital markets have responded to regulatory uncertainty with caution. Venture capital investment in hemp-derived cannabinoid companies declined 45% in 2025 compared to 2024, according to data from Viridian Capital Advisors. Investors cite regulatory risk as the primary concern, with the potential for state-level bans or restrictions making long-term business planning difficult. Wholesale pricing for hemp biomass and isolates has fluctuated significantly based on regulatory developments. CBD isolate wholesale prices declined from $3.50 per gram in January 2024 to $1.20 per gram in December 2025 as oversupply and regulatory uncertainty pressured margins. Delta-8 THC distillate wholesale prices similarly declined from $1,800 per kilogram in mid-2024 to $600 per kilogram in early 2026. The retail landscape is consolidating as regulatory compliance costs increase. Independent smoke shops and convenience stores that previously sold hemp-derived products are exiting the market in states with strict testing and licensing requirements. In Ohio, approximately 30% of retailers that sold hemp-derived cannabinoids before House Bill 210 took effect have discontinued those product lines rather than pursue state licensing. Insurance markets have tightened for hemp-derived cannabinoid businesses. General liability insurers increasingly exclude hemp-derived intoxicating products from coverage or charge substantial premiums. A hemp edibles manufacturer in Colorado reported liability insurance premiums increasing from $18,000 annually in 2024 to $67,000 in 2026, with coverage limits reduced from $2 million to $1 million.

What Experts Say

Industry stakeholders, regulators, and policy experts offer divergent perspectives on optimal approaches to hemp-derived cannabinoid regulation, with debate centering on consumer safety, market fairness, and federalism. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has stated that outright bans on hemp-derived cannabinoids are legally questionable and economically harmful. According to Miller, states should establish regulatory frameworks with testing requirements and age restrictions rather than prohibitions. He has argued that the 2018 Farm Bill intended to create a legal hemp industry and that overly restrictive state laws undermine that federal policy. Shannon Malone, executive director of the Cannabis Regulators Association, has expressed concern that unregulated hemp-derived intoxicating products create public health risks and undermine state-licensed cannabis programs. According to Malone, states should require intoxicating hemp products to meet the same testing, labeling, and distribution standards as marijuana products. She has noted that the regulatory gap between hemp and marijuana creates consumer confusion and market distortions. Dr. Ryan Vandrey, a professor of psychiatry and behavioral sciences at Johns Hopkins University who studies cannabis, has raised concerns about the lack of standardization in hemp-derived products. According to Vandrey, studies have found significant discrepancies between labeled and actual cannabinoid content in hemp products, with some products containing far more THC than labels indicate. He has called for mandatory testing and accurate labeling to protect consumers. Steve Schain, an attorney who represents hemp businesses, has argued that delta-8 THC and similar cannabinoids derived from legal hemp are themselves legal under the 2018 Farm Bill. According to Schain, the DEA lacks authority to regulate hemp-derived substances, and state restrictions may be preempted by federal law. He has represented hemp companies in legal challenges to state bans. Andrew Kline, a partner at Perkins Coie who advises cannabis companies, has stated that the hemp-derived cannabinoid market exists in a legal gray area that creates risks for all participants. According to Kline, the lack of clear federal guidance from the FDA and DEA has created a regulatory vacuum that states are attempting to fill with inconsistent approaches. He has advised clients that regulatory clarity is essential for long-term market stability. Larisa Bolivar, executive director of the Cannabis Consumers Coalition, has emphasized the importance of consumer access to affordable cannabinoid products. According to Bolivar, hemp-derived products provide options for consumers in states without legal marijuana programs or where marijuana prices remain prohibitively high. She has advocated for regulatory frameworks that ensure product safety while maintaining consumer access.

What's Next

The remainder of 2026 will see continued state legislative activity, potential federal regulatory action, and ongoing legal challenges that will shape the hemp-derived cannabinoid market through 2027 and beyond. At least fifteen states have hemp cannabinoid bills pending in committee as of May 2026. Key legislation to watch includes Florida Senate Bill 1698, which could establish a major regulated hemp market if enacted, and North Carolina Senate Bill 711, which would create regulatory standards in one of the largest unregulated hemp markets. Legislative sessions in most states conclude by June 2026, with any bills not passed by then requiring reintroduction in 2027. The FDA is expected to issue guidance on hemp-derived CBD by the end of 2026, according to statements from agency officials in congressional testimony in March 2026. The guidance could establish a regulatory pathway for CBD as a dietary supplement or food ingredient, potentially providing federal clarity that has been absent since the 2018 Farm Bill. However, the FDA has missed previous self-imposed deadlines for CBD guidance, and further delays are possible. The Fifth Circuit Court of Appeals is scheduled to hear oral arguments in July 2026 in a case challenging the DEA's authority to regulate hemp-derived delta-8 THC. The court's decision could have nationwide implications for the legal status of synthetically derived cannabinoids from hemp. A ruling favoring hemp industry plaintiffs could limit DEA enforcement authority, while a ruling supporting the DEA could provide legal foundation for state restrictions. The 2026 election cycle may influence hemp policy in several states. Gubernatorial races in states including Florida, Georgia, and Ohio could bring leadership changes that affect regulatory priorities. Ballot initiatives related to marijuana legalization in several states could also impact hemp markets by creating alternative legal sources of intoxicating cannabinoids. The USDA is expected to release updated guidance on hemp testing protocols in late 2026, according to the agency's regulatory agenda. The guidance may address concerns about testing timeline requirements and total THC measurement methodologies that have created compliance challenges for farmers. Industry stakeholders have requested more flexible testing windows and clearer standards for remediation of non-compliant crops. International developments may influence U.S. hemp policy. The European Union is developing a regulatory framework for hemp-derived CBD products, with proposed regulations expected in 2027. Canada has integrated hemp-derived cannabinoids into its Cannabis Act regulatory framework. These international approaches may inform U.S. policy discussions. Market consolidation is likely to continue as regulatory compliance costs increase and smaller operators exit. Larger hemp companies with resources to navigate complex state-by-state requirements are positioned to gain market share. Potential mergers and acquisitions in the hemp sector may accelerate in the second half